TREND : UP
CALL : BUY
For the entire 2014 outlook for pharma particularly companies like Aurobindo, which have a lot of pipeline on the abbreviated new drug application (ANDA) may benefit significantly because they have very clearly moved from the generics to the formulation part. They have kind of made some very good indoors into the US market as well.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.